Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

West Nile Virus and Other Nationally Notifiable Arboviral Diseases — United States, 2016


Article Metrics

Altmetric:

Citations:

Views: Views equals page views plus PDF downloads

Metric Details

MMWR Email Subscription Button
 
Alexis Burakoff, MD1; Jennifer Lehman2; Marc Fischer, MD2; J. Erin Staples, MD, PhD2; Nicole P. Lindsey, MS2 (View author affiliations)

View suggested citation

Summary

What is already known about this topic?

Arboviral disease can cause considerable morbidity and mortality in the United States. West Nile virus (WNV) is consistently found to be the leading cause of domestically acquired arboviral disease, but several other arboviruses cause sporadic cases and outbreaks of neuroinvasive disease.

What is added by this report?

In 2016, WNV continued to be the most common cause of neuroinvasive arboviral disease in the United States, with a similar incidence to the median incidence during 2002–2015. An increase in reported cases of Powassan virus occurred in 2016, with two states reporting their first cases.

What are the implications for public health practice?

Arboviral diseases are a continuing source of severe illness each year. Surveillance remains important to identify outbreaks and guide prevention strategies.

Arthropod-borne viruses (arboviruses) are transmitted to humans primarily through the bites of infected mosquitoes and ticks. West Nile virus (WNV) is the leading cause of domestically acquired arboviral disease in the continental United States (1,2). Other arboviruses, including La Crosse, Powassan, Jamestown Canyon, St. Louis encephalitis, and eastern equine encephalitis viruses, cause sporadic cases of disease and occasional outbreaks. This report summarizes surveillance data reported to CDC for 2016 for nationally notifiable arboviruses. It excludes dengue, chikungunya, and Zika viruses, as these are primarily nondomestic viruses typically acquired through travel. Forty-seven states and the District of Columbia (DC) reported 2,240 cases of domestic arboviral disease, including 2,150 (96%) WNV disease cases. Of the WNV disease cases, 1,310 (61%) were classified as neuroinvasive disease (e.g., meningitis, encephalitis, acute flaccid paralysis), for a national incidence of 0.41 cases per 100,000 population. After WNV, the most frequently reported arboviruses were La Crosse (35 cases), Powassan (22), and Jamestown Canyon (15) viruses. Because arboviral diseases continue to cause serious illness, maintaining surveillance is important to direct prevention activities.

Arboviruses are maintained in a transmission cycle between arthropods and vertebrate hosts, including humans and other animals. Humans primarily become infected when bitten by an infected tick or mosquito. Person-to-person transmission through blood transfusion and organ transplantation has been reported but is uncommon (3). Most human infections are asymptomatic; symptomatic infections commonly manifest as a systemic febrile illness and, less commonly as neuroinvasive disease.

Most endemic arboviral diseases are nationally notifiable and are reported to CDC through ArboNET, a national arboviral surveillance system managed by CDC and state health departments (3,4). Using standard definitions, human cases with laboratory evidence of recent arboviral infection are classified as having either neuroinvasive or non-neuroinvasive disease (3). Cases reported as encephalitis, meningitis, acute flaccid paralysis, or other neurologic manifestations were categorized as neuroinvasive disease. Reports without indication of a central neurologic process were categorized as non-neuroinvasive disease. Acute flaccid paralysis can occur with or without encephalitis or meningitis. In this report, any case reported as acute flaccid paralysis (with or without another clinical syndrome) was classified as acute flaccid paralysis and not included in the other categories. Because ArboNET is a passive surveillance system, detection and reporting of neuroinvasive disease are thought to be more consistent and more complete than non-neuroinvasive disease, which is likely considerably underreported. For this reason, incidence rates were calculated using neuroinvasive disease cases and the U.S. Census 2016 mid-year population estimates.

In 2016, 2,240 cases of domestic arboviral diseases were reported to CDC. Cases were caused by WNV (2,150 cases, 96%), La Crosse virus (35), Powassan virus (22), Jamestown Canyon virus (15), St. Louis encephalitis virus (eight), eastern equine encephalitis virus (seven), and unspecified California serogroup virus (three). Of the 3,142 U.S. counties, 656 (21%) reported one or more cases of arboviral disease. No cases of domestic arboviral disease were reported from Alaska, Hawaii, or Delaware.

Overall, 2,150 WNV disease cases were reported from 604 counties in 45 states and the District of Columbia. Of these, 1,310 (61%) cases were neuroinvasive and 1,781 (83%) patients had illness onset during July–September (Table 1). The median age of patients was 57 years (interquartile range [IQR] = 44–68 years); 1,326 (62%) were male. A total of 1,465 (68%) patients were hospitalized and 106 (5%) died. The median age of patients who were hospitalized was 61 years (IQR = 48–72 years) and 947 (65%) were male. The median age of patients who died was 75 years (IQR = 62–82 years) and 63 (59%) were male.

Among the 1,310 WNV neuroinvasive disease cases, 689 (53%) were reported as encephalitis, 468 (36%) as meningitis, 78 (6%) as acute flaccid paralysis, and 75 (6%) as other neurologic presentation. Of the 78 patients with reported acute flaccid paralysis, 44 (56%) also had reported encephalitis or meningitis. Among patients with neuroinvasive disease, 1,250 (95%) were hospitalized and 105 (8%) died. The incidence of neuroinvasive WNV disease in the United States was 0.41 per 100,000 population (Table 2). South Dakota (4.04 per 100,000), North Dakota (3.17), Nebraska (1.84), Wyoming (1.37), and Colorado (1.06) had the highest incidence rates (Table 2) (Figure).The largest number of cases were reported from California (335), Texas (252) and Illinois (98), which together accounted for just over half of neuroinvasive disease cases (52%). The incidence of WNV neuroinvasive disease increased with age, from 0.02 per 100,000 in children aged <10 years to 1.16 in adults aged ≥70 years. Incidence was higher among males (0.54 per 100,000) than among females (0.28).

Thirty-five La Crosse virus disease cases were reported from six states (Minnesota, North Carolina, Ohio, Tennessee, Wisconsin, and West Virginia), including 31 (89%) that were neuroinvasive (Table 1). Illness onset ranged from May through October, with 25 (71%) patients reporting onset during July–September. Twenty-five (71%) patients were male. The median age was 9 years (IQR = 5–12 years) and 28 (80%) were aged <18 years. Thirty-two (91%) patients were hospitalized; none died. Among patients hospitalized, 29 (91%) had neuroinvasive disease. Incidence of La Crosse virus neuroinvasive disease was highest in West Virginia (0.27 per 100,000) (Table 2).

Twenty-two Powassan virus disease cases were reported from nine states (Connecticut, Maine, Massachusetts, Minnesota, New Hampshire, New York, North Carolina, Rhode Island, and Wisconsin). Illness onset dates ranged from February through December. The median age of patients was 66 years (IQR = 61–72 years) and 14 (64%) were male. Twenty-one (95%) cases were neuroinvasive. Twenty (91%) patients were hospitalized and three (14%) died.

Fifteen Jamestown Canyon virus disease cases were reported from three states (Massachusetts, Minnesota, and Wisconsin). Illness onset dates ranged from June through November, with 11 (73%) of those patients reporting onset during July–September. The median age of patients was 64 years (IQR = 44–70 years) and 12 (80%) were male. Seven (47%) cases were neuroinvasive, seven (47%) patients were hospitalized, and none died.

Eight cases of St. Louis encephalitis virus disease were reported from four states (California, Illinois, Nevada, and Utah). The median age of patients was 64 years (IQR = 56–74) and five (63%) were male. Illness onset dates ranged from June through September. Seven (88%) cases were neuroinvasive (Table 1). All eight patients were hospitalized and two (25%) died.

Seven cases of eastern equine encephalitis virus disease were reported from five states (Georgia, Michigan, Montana, New Jersey, and North Carolina); all were neuroinvasive disease. The median age of patients was 63 years (IQR = 39–71 years) and six (86%) were male. Illness onset dates ranged from July through October. All patients were hospitalized and three (43%) died.

Discussion

As in previous years, in 2016, WNV remained the most common cause of neuroinvasive arboviral disease in the continental United States, accounting for 95% of reported neuroinvasive disease cases. The incidence of WNV neuroinvasive disease in 2016 (0.41 per 100,000) was the same as the median incidence during 2002–2015 (2). The case fatality rate for neuroinvasive disease cases (8%) was comparable to that reported in past years (median of 9% for 1999–2015).

La Crosse virus continued to be more frequently reported in children than in other age groups (5). Overall, however, fewer cases of La Crosse virus were reported in 2016 than in any year in the past decade. More cases of Powassan virus were reported in 2016 than in previous years (22 in 2016 compared with a median of seven cases each year during 2006–2015) (6). This increase was, in part, likely caused by increased awareness and testing for the virus. In 2016, Powassan virus disease was reported for the first time in Connecticut and Rhode Island (6). The patient from North Carolina had history of travel to a state with previously documented Powassan virus transmission. Three states (California, Illinois, and Utah) reported cases of St. Louis encephalitis virus disease for the first time in >10 years. However, fewer cases were reported than in 2015, a year in which an outbreak in Arizona occurred (7). Eastern equine encephalitis virus was again the domestic arboviral disease with the highest fatality rate, with four deaths reported among the seven patients with neuroinvasive disease. Cases were reported from states that have historically reported eastern equine encephalitis virus, with the exception of a case from Montana, where the infection was acquired in a state with previously documented transmission.

Arboviruses continue to cause substantial morbidity in the United States, although reported numbers of cases vary annually. Cases occur sporadically, and the epidemiology varies by virus and geographic area. Consistent with past years, in 2016 just over 85% of arboviral disease cases occurred during April–September. Weather, zoonotic host and vector abundance, and human behavior are all factors that can influence when and where outbreaks occur. These factors make it difficult to predict future locations and timing of cases and help to emphasize the importance of surveillance to identify outbreaks and inform public health prevention efforts.

The findings in this report are subject to at least two limitations. First, ArboNET is a passive surveillance system, which leads to an underestimation of the actual prevalence of disease. To be reported as a disease case, the person affected must seek care, a clinician must request appropriate diagnostic tests, and health care providers and laboratories must then report cases to public health authorities. Previous studies have estimated that between 30 and 70 non-neuroinvasive disease cases occur for every reported case of WNV neuroinvasive disease (810). Based on the number of neuroinvasive disease cases reported in 2016, between 39,300 and 91,700 non-neuroinvasive disease cases of WNV would have been expected to occur; however, only 840 (1%–2%) were reported. Second, because ArboNET does not require information about clinical signs and symptoms or laboratory findings, cases might be misclassified.

It is important for health care providers to consider arboviral infections in the differential diagnosis of cases of aseptic meningitis and encephalitis, obtain appropriate specimens for laboratory testing, and promptly report cases to public health authorities (2). Understanding the epidemiology, seasonality, and geographic distribution of these viruses will assist with clinical recognition and potential differentiation from other neuroinvasive etiologies. Because human vaccines against domestic arboviruses are not available, prevention depends on community and household efforts to reduce vector populations (e.g., applying insecticides and reducing breeding sites), personal protective measures to decrease exposure to mosquitoes and ticks (e.g., use of repellents and wearing protective clothing), and screening of blood donors.

Acknowledgments

ArboNET surveillance coordinators in state and local health departments.

Conflict of Interest

No conflicts of interest were reported.

Corresponding author: Nicole Lindsey, nplindsey@cdc.gov, 970-221-6400.


1Epidemic Intelligence Service, CDC; 2Arboviral Diseases Branch, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC.

References

  1. Reimann CA, Hayes EB, DiGuiseppi C, et al. Epidemiology of neuroinvasive arboviral disease in the United States, 1999–2007. Am J Trop Med Hyg 2008;79:974–9. PubMed
  2. CDC. West Nile virus: statistics & maps. Fort Collins, CO: US Department of Health and Human Services, CDC; 2015. https://www.cdc.gov/westnile/statsMaps/index.html
  3. CDC. Arboviral diseases, neuroinvasive and non-neuroinvasive: 2015 case definition. Atlanta, GA: US Department of Health and Human Services, CDC; 2014. https://wwwn.cdc.gov/nndss/conditions/arboviral-diseases-neuroinvasive-and-non-neuroinvasive/case-definition/2015/
  4. Lindsey NP, Staples JE, Lehman JA, Fischer M. Surveillance for human West Nile virus disease—United States, 1999–2008. MMWR Surveill Summ 2010;59(No. SS-2). PubMed
  5. Gaensbauer JT, Lindsey NP, Messacar K, Staples JE, Fischer M. Neuroinvasive arboviral disease in the United States: 2003 to 2012. Pediatrics 2014;134:e642–50. CrossRef PubMed
  6. Tutolo JW, Staples JE, Sosa L, Bennett N. Notes from the field: Powassan virus disease in an infant—Connecticut, 2016. MMWR Morb Mortal Wkly Rep 2017;66:408–9. CrossRef PubMed
  7. Venkat H, Krow-Lucal E, Hennessey M, et al. Notes from the field: concurrent outbreaks of St. Louis encephalitis virus and West Nile virus disease—Arizona, 2015. MMWR Morb Mortal Wkly Rep 2015;64:1349–50. PubMed
  8. Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001;358:261–4. CrossRef PubMed
  9. Busch MP, Wright DJ, Custer B, et al. West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis 2006;12:395–402. CrossRef PubMed
  10. Carson PJ, Borchardt SM, Custer B, et al. Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999–2008. Emerg Infect Dis 2012;18:684–6. CrossRef PubMed
TABLE 1. Number and percentage of reported cases of West Nile virus and other arboviral diseases, by virus type and selected patient characteristics — United States, 2016*
Characteristic Virus type, no. (%)
West Nile La Crosse Powassan Jamestown Canyon Saint Louis encephalitis Eastern equine encephalitis
(N = 2,150) (N = 35) (N = 22) (N = 15) (N = 8) (N = 7)
Age group (yrs)
<18 61 (3) 28 (80) 1 (5) 0 (0) 0 (0) 1 (14)
18–59 1,152 (54) 5 (14) 2 (9) 7 (47) 4 (50) 2 (29)
≥60 937 (44) 2 (6) 19 (86) 8 (53) 4 (50) 4 (57)
Sex
Male 1,326 (62) 25 (71) 14 (64) 12 (80) 5 (63) 6 (86)
Female 824 (38) 10 (29) 8 (36) 3 (20) 3 (38) 1 (14)
Period of illness onset
January–March 2 (<1) 0 (0) 1 (5) 0 (0) 0 (0) 0 (0)
April–June 88 (4) 4 (11) 6 (27) 1 (7) 1 (13) 0 (0)
July–September 1,781 (83) 25 (71) 3 (14) 11 (73) 7 (88) 6 (86)
October–December 279 (13) 6 (17) 12 (55) 3 (20) 0 (0) 1 (14)
Clinical syndrome
Non-neuroinvasive 840 (39) 4 (11) 1 (5) 8 (53) 1 (13) 0 (0)
Neuroinvasive 1,310 (61) 31 (89) 21 (95) 7 (47) 7 (88) 7 (100)
Encephalitis 689 (32) 24 (69) 15 (68) 4 (27) 6 (75) 6 (86)
Meningitis 468 (22) 6 (17) 3 (14) 2 (13) 0 (0) 0 (0)
AFP 78 (4) 0 (0) 1 (5) 0 (0) 0 (0) 0 (0)
Other 75 (3) 1 (3) 2 (9) 1 (7) 1 (13) 1 (14)
Outcome
Hospitalization 1,465 (68) 32 (91) 20 (91) 7 (47) 8 (100) 7 (100)
Death 106 (5) 0 (0) 3 (14) 0 (0) 2 (25) 3 (43)

Abbreviation: AFP = acute flaccid paralysis.
* Three unspecified California serogroup virus cases were also reported.
Of the 78 West Nile virus disease patients with AFP, 44 (56%) also had encephalitis or meningitis; the additional AFP patient with Powassan virus also had encephalitis.

TABLE 2. Number and rate* of reported cases of arboviral neuroinvasive disease, by virus type, U.S. Census division, and state — United States, 2016
U.S. Census division/State Virus type
West Nile La Crosse Powassan Jamestown Canyon Saint Louis encephalitis Eastern equine encephalitis
No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate
United States 1,310 0.41 31 0.01 21 0.01 7 <0.01 7 <0.01 7 <0.01
New England 15 0.10 9 0.06 1 0.01
Connecticut 1 0.03 1 0.03
Maine 1 0.08
Massachusetts 10 0.15 5 0.07 1 0.01
New Hampshire 1 0.07
Rhode Island 2 0.19 1 0.09
Vermont 2 0.32
Middle Atlantic 43 0.10 1 <0.01 1 <0.01
New Jersey 11 0.12 1 0.01
New York 20 0.10 1 0.01
Pennsylvania 12 0.09
East North Central 177 0.38 12 0.03 5 0.01 5 0.01 1 <0.01 2 <0.01
Illinois 98 0.77 1 0.01
Indiana 15 0.23
Michigan 42 0.42 2 0.02
Ohio 12 0.10 9 0.08
Wisconsin 10 0.17 3 0.05 5 0.09 5 0.09
West North Central 175 0.81 3 0.01 5 0.02 1 <0.01
Iowa 16 0.51
Kansas 18 0.62
Minnesota 38 0.69 3 0.05 5 0.09 1 0.02
Missouri 9 0.15
Nebraska 35 1.84
North Dakota 24 3.17
South Dakota 35 4.04
South Atlantic 32 0.05 13 0.02 1 <0.01 3 <0.01
Delaware
District of Columbia 1 0.15
Florida 6 0.03
Georgia 5 0.05 1 0.01
Maryland 6 0.10
North Carolina 2 0.02 8 0.08 1§ 0.01 2 0.02
South Carolina 6 0.12
Virginia 6 0.07
West Virginia 5 0.27
East South Central 48 0.25 3 0.02
Alabama 13 0.27
Kentucky 5 0.11
Mississippi 27 0.90
Tennessee 3 0.05 3 0.05
West South Central 319 0.80
Arkansas 8 0.27
Louisiana 38 0.81
Oklahoma 21 0.54
Texas 252 0.90
Mountain 156 0.65 3 0.01 1 <0.01
Arizona 57 0.82
Colorado 59 1.06
Idaho 3 0.18
Montana 3 0.29 1§ 0.10
Nevada 13 0.44 2 0.07
New Mexico 6 0.29
Utah 7 0.23 1 0.03
Wyoming 8 1.37
Pacific 345 0.65 3 0.01
Alaska
California 335 0.85 3 0.01
Hawaii
Oregon 2 0.05
Washington 8 0.11

* Per 100,000 population, based on July 1, 2016, U.S. Census population estimates.
Dashes indicate none reported.
§ Patient reported travel to a state with a history of the virus.

Return to your place in the textFIGURE. Rate* of reported cases of West Nile virus neuroinvasive disease — United States, 2016
The figure above is a map of the United States showing the rate of reported cases of West Nile virus neuroinvasive disease, by state, in 2016.

* Per 100,000 population.

The figure above is a map of the United States showing the rate of reported cases of West Nile virus neuroinvasive disease, by state, in 2016.

Suggested citation for this article: Burakoff A, Lehman J, Fischer M, Staples JE, Lindsey NP. West Nile Virus and Other Nationally Notifiable Arboviral Diseases — United States, 2016. MMWR Morb Mortal Wkly Rep 2018;67:13–17. DOI: http://dx.doi.org/10.15585/mmwr.mm6701a3.

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

TOP